Citations

Clear

4610 citation(s) found for "Lu, Brian".

AOSSM Early Sport Specialization Consensus Statement
LaPrade, Robert F. , Agel, Julie , Brenner, Joel S. , Cordasco, Frank A. , Feeley, Brian T. , Gould, Daniel , Hainline, Brian , Hewett, Timothy E. , Jayanthi, Neeru , Myer, Gregory D. , Nissen, Carl W. , Provencher, Matthew T. , Hewett, Timothy, Baker, Joseph R. , Cote, Jean Maxime , Engebretsen, Lars , Feeley, Brian T. , Kocher, Mininder Singh , Philippon, Marc J. , Myer, Gregory D , LaPrade, Robert F

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 29, 2016 | Volume: 4 | Issue: 4 | Pages: No page available

10.1177/2325967116644241 | PMID 27169132 Get It

Background: Early sport specialization is not a requirement for success at the highest levels of competition and is believed to be unhealthy physically and mentally for young athletes. It also discourages unstructured free play, which has many benefits. Purpose: To review the available evidence on early sports specialization and identify areas where scientific data are lacking. Study Design: Think tank, roundtable discussion. Results: The primary outcome of this think tank was that there is no evidence that young children will benefit from early sport specialization in the majority of sports. They are subject to overuse injury and burnout from concentrated activity. Early multisport participation will not deter young athletes from long-term competitive athletic success. Conclusion: Youth advocates, parents, clinicians, and coaches need to work together with the sport governing bodies to ensure healthy environments for play and competition that do not create long-term health issues yet support athletic competition at the highest level desired.
Elementary School–Based Obesity Intervention Using an Educational Curriculum
Lynch, Brian , Gentile, Natalie, Maxson, Julie, Quigg, Stephanie, Swenson, L, Kaufman, Tara K. , Lynch, Brian A, Swenson, Laura, Kaufman, Tara

Mayo Clinic

Journal of Primary Care & Community Health | April 28, 2016 | Volume: 7 | Issue: 4 | Pages: 265-271

10.1177/2150131916644888 | PMID 27121724 Get It

Background: Pediatric obesity is a significant public health problem with a prevalence of 16.9% among US children. School-based obesity interventions show promise for reducing adiposity in elementary age children. This pilot study evaluated the impact of the Let’s Go! 5-2-1-0 pediatric obesity intervention program in an elementary school setting. Methods: This was a cluster randomized controlled field trial comprising 8 classrooms of second- and third-grade children. The impact of implementation of a standardized 5-2-1-0 curriculum was evaluated in the classrooms by looking at health behavior (self-reported fruit and vegetable and sugar-containing beverage intake, and screen time), physical activity (steps measured by pedometer), and body mass index (BMI). Half of the classrooms were given 5-2-1-0 teaching over a 4-month period. Results: There was no statistical difference in improvement of healthy habits, BMI, or physical activity in the intervention group compared with the control group. Conclusions: The 5-2-1-0 intervention used in this study was feasible. There was no significant change in healthy habits, likely due to the small number of participants in the study. The intervention and control sites were in different classrooms and there could be factors such as teacher enthusiasm, socioeconomic factors, and individual traits affecting habits. Future studies could use pre- and post-intervention quizzes to assess healthy habits knowledge retention, involving the environments the child participates in outside of school, using research-grade pedometers or accelerometers for measuring activity data collection, and recruiting larger samples to ensure adequate statistical power.
Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine
Hiemstra, Jessica A., Lee, Dong I. , Chakir, Khalid, Gutiérrez‐Aguilar, Manuel , Marshall, Kurt D., Zgoda, Pamela J., Rivera, Noelany Cruz, Dozier, Daniel G., Ferguson, Brian S. , Heublein, Denise M., Burnett, John C. , Scherf, Carolin, Ivey, Jan, Minervini, Gianmaria, McDonald, Kerry S. , Baines, Christopher , Krenz, Maike , Domeier, Timothy L. , Emter, Craig A.

Mayo Clinic

Journal of the American Heart Association | April 21, 2016 | Volume: 5 | Issue: 4 | Pages: No page available

10.1161/jaha.116.003277 | PMID 27098966 Get It

Background Cyclic guanosine monophosphate‐protein kinase G‐phosphodiesterase 5 signaling may be disturbed in heart failure ( HF ) with preserved ejection fraction, contributing to cardiac remodeling and dysfunction. The purpose of this study was to manipulate cyclic guanosine monophosphate signaling using the dipeptidyl‐peptidase 4 inhibitor saxagliptin and phosphodiesterase 5 inhibitor tadalafil. We hypothesized that preservation of cyclic guanosine monophosphate cGMP signaling would attenuate pathological cardiac remodeling and improve left ventricular ( LV ) function. Methods and Results We assessed LV hypertrophy and function at the organ and cellular level in aortic‐banded pigs. Concentric hypertrophy was equal in all groups, but LV collagen deposition was increased in only HF animals. Prevention of fibrotic remodeling by saxagliptin and tadalafil was correlated with neuropeptide Y plasma levels. Saxagliptin better preserved integrated LV systolic and diastolic function by maintaining normal LV chamber volumes and contractility (end‐systolic pressure‐volume relationship, preload recruitable SW ) while preventing changes to early/late diastolic longitudinal strain rate. Function was similar to the HF group in tadalafil‐treated animals including increased LV contractility, reduced chamber volume, and decreased longitudinal, circumferential, and radial mechanics. Saxagliptin and tadalafil prevented a negative cardiomyocyte shortening‐frequency relationship observed in HF animals. Saxagliptin increased phosphodiesterase 5 activity while tadalafil increased cyclic guanosine monophosphate levels; however, neither drug increased downstream PKG activity. Early mitochondrial dysfunction, evident as decreased calcium‐retention capacity and Complex II ‐dependent respiratory control, was present in both HF and tadalafil‐treated animals. Conclusions Both saxagliptin and tadalafil prevented increased LV collagen deposition in a manner related to the attenuation of increased plasma neuropeptide Y levels. Saxagliptin appears superior for treating heart failure with preserved ejection fraction, considering its comprehensive effects on integrated LV systolic and diastolic function.
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations
Fehringer, Gordon , Kraft, Peter , Eeles, Rosalind A. , Chatterjee, Nilanjan , Schumacher, Fredrick R. , Schildkraut, Joellen M. , Lindström, Sara , Brennan, Paul , Bickeböller, Heike , Houlston, Richard S. , Landi, Maria Teresa , Caporaso, Neil E. , Risch, Angela , Olama, Ali Amin Al , Berndt, Sonja I. , Giovannucci, Edward L. , Grönberg, Henrik , Muir, Kenneth , Stampfer, Meir J. , Stevens, Victoria L. , Goode, Ellen L. , Reid, Brett M. , Brenner, Hermann , Chang‐Claude, Jenny , Kocarnik, Jonathan K., Slattery, Martha L. , Adank, Muriel A. , Ahsan, Habibul , Aittomäki, Kristiina, Baglietto, Laura , Blomquist, Carl, Canzian, Federico , Eliassen, A. Heather , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Fletcher, Olivia , García‐Closas, Montserrat , Gaudet, Mia M. , Johnson, Nichola , Hazra, Aditi , Hein, Rebecca, Hofman, Albert , Irwanto, Astrid , Johansson, Mattias , Lichtner, Peter , Liu, Jianjun , Lund, Eiliv , Makalic, Enes , Meindl, Alfons , Müller‐Myhsok, Bertram , Muranen, Taru , Peeters, Petra H., Peto, Julian, Prentice, Ross L. , Sánchez, María‐José , Schmutzler, Rita K. , Southey, Melissa C. , Travis, Ruth C. , Turnbull, Clare , Uitterlinden, André G. , Wang, Zhaoming , Whittemore, Alice S. , Yang, Xiaohong R. , Zheng, Wei , Buchanan, Daniel D. , Casey, Graham , Conti, David V. , Edlund, Christopher K., Gallinger, Steven , Haile, Robert W. , Jenkins, Mark A. , Li, Li , Lindor, Noralene M., Schmit, Stephanie L. , Thibodeau, Stephen N. , Woods, Michael O. , Rafnar, Þórunn , Guðmundsson, Jūlı́us, Stacey, Simon , Stefánsson, Kāri , Sulem, Patrick , Chen, Y. Ann , Wei, Yongyue , Shen, Hongbing , Hu, Zhibin , Obeidat, Ma’en , Nickle, David C. , Timens, Wim , Freedman, Matthew L. , Seminara, Daniela, Gong, Jian , Peters, Ulrike , Gruber, Stephen B. , Sellers, Thomas A. , Easton, Douglas F. , Hunter, David J. , Haiman, Christopher A. , Henderson, Brian E., Hung, Rayjean J., Batra, Jyotsna , Hung, Rayjean J. , Pharoah, Paul D.P. , Kote‐Jarai, Zsofia , Ma, Jing , Wiklund, Fredrik E. , Willett, Walter C. , Permuth, Jennifer B. , Risch, Harvey A. , Bezieau, Stéphane , Chan, Andrew T. , Hudson, Thomas J , Newcomb, Polly A. , Schoen, Robert E. , White, Emily E. , Czene, Kamila , dos‐Santos‐Silva, Isabel , Hall, Per N , Hopper, John L. , Kaaks, Rudolf , Kibriya, Muhammad Ghulam , Meindl, Alfons , Nevanlinna, Heli , Rahman, Nazneen , Schmidt, Daniel F. , Tamimi, Rulla M. , Marchand, Loı̈c Le , Tyrer, Jonathan P. , Christiani, David C. , Shu, Xiao‐Ou , Shiraishi, Kouya , Takahashi, Atsushi , Bossé, Yohan , Li, Qiyuan , Chanock, Stephen Jacob , Amos, Christopher I. , Hung, Rayjean J., Buchanan, Daniel D , Houlston, Richard S , Eeles, Rosalind A , Southey, Melissa C , Jenkins, Mark A , Canzian, Federico , Hung, Rayjean J , Muir, Kenneth , Travis, Ruth C , Haile, Robert W , Wang, Zhaoming , Brenner, Hermann , Muranen, Taru A , García-Closas, Montserrat , Makalic, Enes , Kraft, Peter , Zheng, Wei , Figueroa, Jonine D , Eliassen, A Heather , Conti, David V , Batra, Jyotsna , Johansson, Mattias , Baglietto, Laura , Fletcher, Olivia , Sánchez, Maria-Jose , Risch, Angela , Bickeböller, Heike , Shen, Hongbing , Timens, Wim , Liu, Jing

Mayo Clinic

Cancer Research | April 21, 2016 | Volume: 76 | Issue: 17 | Pages: 5103-5114

10.1158/0008-5472.can-15-2980 | PMID 27197191 Get It

Abstract Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer. This is the largest study to date examining pleiotropy across multiple cancer-associated loci, identifying common mechanisms of cancer development and progression. Cancer Res; 76(17); 5103–14. ©2016 AACR.
Target-enrichment sequencing and copy number evaluation in inherited polyneuropathy
Wang, Wei , Dawson, D. Brian, Thorland, Erik C., Lundquist, Patrick A. , Eckloff, Bruce W., Baheti, Saurabh , Evans, Jared M., Scherer, Steven S. , Dyck, P. James B. , Klein, Christopher J. , Wang, Chen , Wu, Yanhong , Klein, Christopher J

Mayo Clinic

Neurology | April 14, 2016 | Volume: 86 | Issue: 19 | Pages: 1762-1771

10.1212/wnl.0000000000002659 | PMID 27164712 Get It

The safety of vedolizumab for ulcerative colitis and Crohn's disease
Rutgeerts, Paul, Sandborn, William J. , Danese, Silvio , D’Haens, Geert , Loftus, Edward V. , Sankoh, Serap, Fox, Irving H., Parikh, Asit, Milch, Catherine , Abhyankar, Brihad, Feagan, Brian G. , Colombel, Jean‐Frédéric , Sands, Bruce E , Panaccione, Remo , Loftus, Edward V , Danese, Silvio

Mayo Clinic

Gut | April 13, 2016 | Volume: 66 | Issue: 5 | Pages: 839-851

10.1136/gutjnl-2015-311079 | PMID 26893500 Get It

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ≤5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number NCT01177228, NCT00619489 , NCT00783718 , NCT00783692 , NCT01224171 , NCT00790933 .
Preeclampsia/Eclampsia candidate genes show altered methylation in maternal leukocytes of preeclamptic women at the time of delivery
Sun, Zhifu , Borowski, Kristi, Davies, Norman, Rose, Carl H., White, Wendy M, Borowski, Kristi S, Brost, Brian C, Davies, Norman P, Garovic, Vesna D. , White, Wendy , Brost, Brian , Sun, Zhifu

Mayo Clinic

Hypertension in Pregnancy | April 11, 2016 | Volume: 35 | Issue: 3 | Pages: 394-404

10.3109/10641955.2016.1162315 | PMID 27064514 Get It

Low incidence of primary biliary cirrhosis (PBC) in the first‐degree relatives of PBC probands after 8 years of follow‐up
Gulamhusein, Aliya , Juran, Brian D., Atkinson, Elizabeth J. , McCauley, Bryan M. , Schlicht, Erik M., Gulamhusein, Aliya F, McCauley, Bryan, Schlicht, Erik, Lazaridis, Konstantinos N.

Mayo Clinic

Liver International | April 10, 2016 | Volume: 36 | Issue: 9 | Pages: 1378-1382

10.1111/liv.13143 | PMID 27062298 Get It

AbstractBackground & AimsPrimary biliary cirrhosis (PBC) is characterized by chronic cholestasis and disease‐specific antimitochondrial antibodies (AMA). A high prevalence of AMAs in first‐degree relatives (FDRs) of PBC probands has been reported, although the natural history of such patients has not been described. We aimed to assess the risk of developing PBC in AMA+ FDRs of patients with PBC.MethodsFirst‐degree relatives recruited to the Mayo Clinic PBC Genetic Epidemiology Registry and Biorepository were followed for disease onset after recruitment. Development of PBC was ascertained via self‐report during a telephone interview and/or via proband report on a questionnaire. Chi‐squared test and t‐test were used to assess the differences between categorical and continuous variables respectively. A mixed‐effects model was used to assess the change in biochemical profiles over time.ResultsForty AMA+ and 423 AMA− subjects were included and followed for a median of 8.9 and 8.4 years respectively. Overall, 3% (n = 15) of FDRs were diagnosed with PBC, and AMA+ FDRs had a higher risk than AMA− FDRs (24% vs. 0.7%, P < 0.01). However, among undiagnosed FDRs, only 4% of AMA+ (n = 1) and 0.4% of AMA− (n = 1) FDRs were diagnosed with PBC (P = 0.17) during the follow‐up period. None of the AMA+ FDRs with normal alkaline phosphatase at baseline developed PBC in follow‐up.ConclusionsOur results suggest a low risk of developing PBC over time in FDRs of patients with PBC, particularly those without biochemical evidence of cholestasis at baseline. These data are useful in counselling and reassuring relatives of their overall favourable prognosis.
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, Brian C. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Malone, Adriana K. , Valcárcel, David , Hamilton, Betty K. , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Warlick, Erica D. , Wirk, Baldeep , Sabloff, Mitchell , Fasan, Omotayo , Gerds, Aaron T. , Marks, David I. , Olsson, Richard F. , Wood, William A. , Costa, Luciano J. , Miller, Alan M. , Cortes, Jörge E. , Daly, Andrew , Kindwall‐Keller, Tamila L. , Kamble, Rammurti T., Rizzieri, David A. , Cahn, Jean‐Yves , William, Basem M. , Litzow, Mark R. , Wiernik, Peter H. , Vij, Ravi , Üstün, Celalettin , Copelan, Edward A. , Kalaycio, Matt, Alyea, Edwin P. , Sobecks, R., Pavletic, Steven Z. , Tallman, Martin S. , Saber, Wael , Nishihori, Taiga , Bacher, Ulrike , Hamilton, Betty, Kharfan-Dabaja, Mohamed A., Cutler, Corey, Warlick, Erica, Wirk, Baldeep Mona, Marks, David, Olsson, Richard, Wood, William Allen, Cortes, Jorge, Kindwall-Keller, Tamila L, Kamble, Rammurti, William, Basem, Savani, Bipin N. , Copelan, Edward, Popat, Uday, Maziarz, Richard, Alyea, Edwin, Sobecks, Ron, Pavletic, Steven, Tallman, Martin, Grunwald, Michael R. , Cutler, Corey S. , Reshef, Ran , Gale, Robert Peter , Liesveld, Jane L. , Popat, Uday R , Maziarz, Richard Thomas , Gerds, Aaron T , Saad, Ayman , Olsson, Richard F , Cortes, Jorge , William, Basem , Costa, Luciano J , Sabloff, Mitchell , Wood, William A , Valcárcel, David

Mayo Clinic

Journal of Clinical Oncology | April 5, 2016 | Volume: 34 | Issue: 16 | Pages: 1864-1871

10.1200/jco.2015.65.0515 | PMID 27044940 Get It

Purpose To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 109/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort. Conclusion The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.